allergic rhinitis
Conditions
Interventions
experiment group:Rupatadine Fumarate
Sponsors
EYE and ENT Hospital of Fudan University
Eligibility
Sex/Gender
All
Age
16 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Male and female patients aged 18-65 years old; 2. patients with definite diagnosis of allergic rhinitis (the diagnostic criteria are detailed in the appendix); 3. nasal symptoms and signs of the total score more than 8 points; 4. agree to participate in this study and sign the informed consent.
Exclusion criteria
Exclusion criteria: 1. non allergic rhinitis (including vasomotor rhinitis, allergic eosinophilic rhinitis, acute rhinitis, chronic rhinitis, atrophic rhinitis, rhinitis etc.), allergic rhinitis and asthma, allergic rhinitis and headache, anatomy and other factors caused by nasal congestion (including severe nasal septum, nasal polyps and nasal inflammation); 2. complicated with ENT diseases and respiratory system (including bronchial asthma, secretory otitis media, etc.), upper respiratory tract infection, and the author with asthma; 3. with postural hypotension and organic heart disease; electrocardiogram found a clinical significance change; 4. patients with thyroid disease, diabetes, hypoglycemia, cardiovascular disease, prostatic hypertrophy, glaucoma and hypertension, scar history, liver function (ALT, AST), renal function (BUN, Cr) 1.5 times higher than the normal value, hematopoietic dysfunction, intestinal diseases, gastric malignant tumor and other serious effects may affect the correct assessment a variety of useful disease history; 5. patients had a history of mental and neuropathy; 6. before the trial, the patients received the following treatment: Immunotherapy within 12 months; Long effect glucocorticoid injection within 3 months; Asimazole in 6 weeks; Systemic or local (inhalation or nasal spray) with glucocorticoid within 1 months; Sodium glycolate or naolometholomethene sodium in 1 months; Long-lasting antihistamine within 1 months; Short effective antihistamine drugs within 1 weeks; 2 weeks of ketotefene, tricyclic antidepressants, macrolide antibiotics and antifungal agents; Systemic or local nasal hyperemia in 24h; Antihistamine active drugs; anticholinergic drugs and antiarrhythmic drugs; Barbiturate, antispasmodic, phentolamine and digitalis; 7. those who are allergic to histamine are known or suspected to be allergic to the research drugs (or similar compounds) or their components; 8. patients who participated in other clinical trials in the last three months; 9. pregnant or lactating women and persons or drivers engaged in dangerous operations; 10. patients with a recent birth plan; 11. poor compliance; 12. researchers think there are any unsuitable candidates.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Effecacy and safety; | — |
Countries
China
Contacts
Public ContactDehui Wang
EYE and ENT Hospital of Fudan University
Outcome results
None listed